Loading organizations...
Key people at Dyee Capital.
Dyee Capital was founded in 2016 by Dezhen Zhu (Founder, Chairman and Managing Partner).
Dyee Capital operates as a private equity firm, strategically investing in the modern service industry. The firm's core approach involves prioritizing opportunities within healthcare, information services, and consumption upgrade sectors. It leverages its accumulated industry knowledge and extensive strategic network to identify valuable investment targets and enhance their long-term value across various vertical markets.
The firm was established in June 2016 by Dezhen Zhu, who serves as its Founder, Chairman, and Managing Partner. Zhu’s foundational insight centered on a commitment to principled investment, aiming to build a trustworthy and supportive growth partner for entrepreneurs, while simultaneously offering a secure investment management platform for its investors. This ethos underpins the firm’s operational philosophy, emphasizing integrity and professionalism.
Dyee Capital serves a dual clientele of entrepreneurs and investors, providing specialized services to both. The firm's long-term vision is to foster subtle yet impactful transformations within its targeted industries and broader society. It achieves this by maintaining a professional, pragmatic, and understated operational style, dedicated to integrating advantageous resources and maximizing value for all its stakeholders.
Key people at Dyee Capital.
Dyee Capital was founded in 2016 by Dezhen Zhu (Founder, Chairman and Managing Partner).
Dyee Capital has 7 tracked investments across 7 companies. The latest tracked deal is $63.2M Series C in Weikaier Pharmaceutical Technology in January 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 2, 2024 | Weikaier Pharmaceutical Technology | $63.2M Series C | — | — |
| Jul 28, 2022 | BridGene Biosciences | $38.5M Series B | Dyee Capital, Junson Capital, Lapam Capital | — |
| Jun 10, 2022 | Degron Therapeutics | $22.0M Series A | Jing YU | Baidu Ventures, Co WIN Ventures, Neux Capital |
| Jan 1, 2022 | GenFleet Therapeutics | $78.5M Series C | Zeng Zhiqiang | Baidu Ventures, CDH Investments, Cherami Investment Group, HM Capital, Lake Bleu Capital, Panlin Capital, Qiaojing Eastern Investment, Shanjin Asset, Suxin Venture Capital |
| Aug 20, 2021 | FABU.ai | $15.4M Series B | Dyee Capital | — |
| Sep 17, 2020 | KYEE | $64.0M Series D | Tencent Holdings | Beijing Meihe Zhongbang Technology, Jiaxing Guangrun, Longmen Capital |
| Sep 1, 2020 | InventisBio | $150.0M Series D | Hillhouse Affiliate GL Ventures | Qiming Venture Partners, Advantech Capital, Aihc Capital, CMB International, Janchor Partners, Lilly Asia Ventures, Matrix Partners China, OrbiMed, Pudong Innotek |